Search Results - "BRAIN, E"

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial by Montemurro, F., Delaloge, S., Barrios, C.H., Wuerstlein, R., Anton, A., Brain, E., Hatschek, T., Kelly, C.M., Peña-Murillo, C., Yilmaz, M., Donica, M., Ellis, P.

“…Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population…”
Get full text

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials by Bradley, Rosie, Braybrooke, Jeremy, Gray, Richard, Hills, Robert, Liu, Zulian, Peto, Richard, Davies, Lucy, Dodwell, David, McGale, Paul, Pan, Hongchao, Taylor, Carolyn, Anderson, Stewart, Gelber, Richard, Gianni, Luca, Jacot, William, Joensuu, Heikki, Moreno-Aspitia, Alvaro, Piccart, Martine, Press, Michael, Romond, Edward, Slamon, Dennis, Suman, Vera, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Wang, Yaochen, Crown, John, de Azambuja, Evandro, Delaloge, Suzette, Fung, Helena, Geyer, Charles, Spielmann, Marc, Valagussa, Pinuccia, Albain, Kathy, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Francis, Prue, Gnant, Michael, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios P, Martín, Miguel, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Regan, Meredith, Robertson, John, Rutgers, Emiel, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Tang, Gong, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Wolmark, Norman, Cameron, David, Bergh, Jonas, Pritchard, Kathleen I, Swain, Sandra M

“…Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer…”
Get full text

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper by Aapro, M., Bernard-Marty, C., Brain, E.G.C., Batist, G., Erdkamp, F., Krzemieniecki, K., Leonard, R., Lluch, A., Monfardini, S., Ryberg, M., Soubeyran, P., Wedding, U.

“…Comorbidities and risk factors likely to complicate treatment are common in elderly cancer patients. Anthracyclines remain the cornerstone of first-line…”
Get full text

Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK by Quaife, S L, Forbes, L J L, Ramirez, A J, Brain, K E, Donnelly, C, Simon, A E, Wardle, J

“…Background: Not recognising a symptom as suspicious is a common reason given by cancer patients for delayed help-seeking; but inevitably this is retrospective…”
Get full text

Influences of cancer symptom knowledge, beliefs and barriers on cancer symptom presentation in relation to socioeconomic deprivation: a systematic review by McCutchan, Grace M, Wood, Fiona, Edwards, Adrian, Richards, Rebecca, Brain, Kate E

“…People from lower socioeconomic groups have worse survival outcomes for cancer, which in part reflects later-stage disease at diagnosis. The mechanisms…”
Get full text

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up by Penel, N., Le Cesne, A., Bui, B.N., Perol, D., Brain, E.G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., Jimenez, M., Duffaud, F., Piperno-Neumann, S., Mignot, L., Blay, J.-Y.

“…Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT). Forty…”
Get full text

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer by Field, John K, Duffy, Stephen W, Baldwin, David R, Brain, Kate E, Devaraj, Anand, Eisen, Tim, Green, Beverley A, Holemans, John A, Kavanagh, Terry, Kerr, Keith M, Ledson, Martin, Lifford, Kate J, McRonald, Fiona E, Nair, Arjun, Page, Richard D, Parmar, Mahesh Kb, Rintoul, Robert C, Screaton, Nicholas, Wald, Nicholas J, Weller, David, Whynes, David K, Williamson, Paula R, Yadegarfar, Ghasem, Hansell, David M

“…Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnosis can save lives. The USA-based National Lung Cancer…”
Get full text

Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? by Forbes, L J L, Simon, A E, Warburton, F, Boniface, D, Brain, K E, Dessaix, A, Donnelly, C, Haynes, K, Hvidberg, L, Lagerlund, M, Lockwood, G, Tishelman, C, Vedsted, P, Vigmostad, M N, Ramirez, A J, Wardle, J

“…Background: There are wide international differences in 1-year cancer survival. The UK and Denmark perform poorly compared with other high-income countries…”
Get full text

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 by Bjelic-Radisic, V., Cardoso, F., Cameron, D., Brain, E., Kuljanic, K., da Costa, R.A., Conroy, T., Inwald, E.C., Serpentini, S., Pinto, M., Weis, J., Morag, O., Lindviksmoen Astrup, G., Tomaszweksi, K.A., Pogoda, K., Sinai, P., Sprangers, M., Aaronson, N., Velikova, G., Greimel, E., Arraras, J., Bottomley, A., Bleiker, Eveline, Bliem, Brigitte, Chie, Weichu, Creutzberg, Carien, Deville, Valerie, Duhoux, Francois, Eilf, Kirsten, Hartup, Sue, Koller, Michael, Nagele, Eva, Nicolatou-Galitis, Ourania, Oberguggenberger, Anne, Schmalz, Claudia, Winters, Zoe

“…The European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23 was one of the first disease-specific questionnaires developed in 1996 to…”
Get full text

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial by Bonnefoi, H., Litière, S., Piccart, M., MacGrogan, G., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Moldovan, C., Bodmer, A., Zaman, K., Cufer, T., Campone, M., Luporsi, E., Malmström, P., Werutsky, G., Bogaerts, J., Bergh, J., Cameron, D.A.

“…Pathological complete response (pCR) following chemotherapy is strongly associated with both breast cancer subtype and long-term survival. Within a phase III…”
Get full text

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients by Pierga, J.-Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L., Mathiot, C., Bidard, F.-C.

“…Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen…”
Get full text

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer by Bidard, F.-C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., Marty, M., Pierga, J.-Y.

“…Circulation of cancer cells in the blood is a mandatory step for metastasis, but circulating tumor cells (CTC) have a low metastatic efficiency in preclinical…”
Get full text

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial by Ignatiadis, M., Litière, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P.A., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, K., Janni, W., Piccart, M., Sotiriou, C., Rack, B., Pierga, J.-Y.

“…Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating…”
Get full text

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer by Porte, B., Carton, M., Lerebours, F., Brain, E., Loirat, D., Haroun, L., Bellesoeur, A., Bach Hamba, S., Kirova, Y., Cottu, P.

“…Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with…”
Get full text

Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study by Webb, Alastair J S, Brain, Susannah A E, Wood, Ruth, Rinaldi, Simon, Turner, Martin R

“…IntroductionEvidence for seasonal variation in incidence and subtype of Guillain-Barré syndrome (GBS) is contradictory, but has implications for provision of…”
Get full text

Different adjuvant chemotherapy regimens in older breast cancer patients? by Wildiers, H., Brain, E.

Get full text

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort by Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., Delaloge, S.

“…Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit…”
Get full text

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients by Jacquet, E., Lardy-Cléaud, A., Pistilli, B., Franck, S., Cottu, P., Delaloge, S., Debled, M., Vanlemmens, L., Leheurteur, M., Guizard, A.V., Laborde, L., Uwer, L., Jacot, W., Berchery, D., Desmoulins, I., Ferrero, J.M., Perrocheau, G., Courtinard, C., Brain, E., Chabaud, S., Robain, M., Bachelot, T.

“…For hormone receptor–positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines…”
Get full text

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer by O'Shaughnessy, J., Campone, M., Brain, E., Neven, P., Hayes, D., Bondarenko, I., Griffin, T.W., Martin, J., De Porre, P., Kheoh, T., Yu, M.K., Peng, W., Johnston, S.

“…Androgen receptor (AR) signaling and incomplete inhibition of estrogen signaling may contribute to metastatic breast cancer (MBC) resistance to a nonsteroidal…”
Get full text

Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1 by Heaton, Bethany J., Jensen, Rebecca L., Line, James, David, Christopher A.W., Brain, Danielle E., Chadwick, Amy E., Liptrott, Neill J.

“…SLC2A1 mediates glucose cellular uptake; key to appropriate immune function. Our previous work has shown efavirenz and lopinavir exposure inhibits T cell and…”
Get full text